BPC-157 TB-500, answered question by question

Definitions and identity

What is the Wolverine peptide blend?

Wolverine is a research-community name for a two-peptide pairing of BPC-157 and TB-500, marketed and discussed as a tissue-repair 'stack.' It is not a single chemical entity, has no single molecular weight or CAS number, and is not an approved product anywhere. The name describes a combination, not a defined molecule.

What is BPC-157 and TB-500?

BPC-157 is a synthetic 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a human gastric-juice protein; TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to residues 17-23 of Thymosin Beta-4 ^[5]. The Wolverine blend pairs the two as a research-community tissue-repair 'stack'; it is not a single chemical entity or an approved product.

What does TB-500 stand for and how does it relate to Thymosin Beta-4?

TB-500 is the research-community name for the synthetic N-acetylated heptapeptide Ac-LKKTETQ, which corresponds to the actin-binding region (residues 17-23) of Thymosin Beta-4 — the ubiquitous 43-amino-acid intracellular G-actin-sequestering protein ^[5]. TB-500 is a fragment of Thymosin Beta-4, and most efficacy data attributed to 'TB-500' were generated with the full-length protein ^[4].

What is the difference between BPC-157 and TB-500?

BPC-157 is a 15-amino-acid pentadecapeptide derived from a gastric-juice protein, acting through VEGFR2-driven angiogenesis and cytoprotection ^[2]. TB-500 is a 7-amino-acid acetylated fragment (Ac-LKKTETQ) of Thymosin Beta-4, acting through G-actin sequestration that regulates cell migration ^[3]. They differ in size, origin, and primary mechanism, which is why they are paired as complementary repair signals.

Mechanism and pairing

Why are BPC-157 and TB-500 combined (the Wolverine stack)?

The rationale is complementary mechanisms: BPC-157 supplies a cytoprotective, pro-angiogenic signal (VEGFR2-Akt-eNOS), while TB-500 supplies an intracellular actin-sequestration signal (1:1 G-actin binding via LKKTETQ) that regulates cell migration ^[2][3]. The two act through complementary but largely non-overlapping pathways — the basis of the 'synergy' claim, which remains a theoretical extrapolation.

How does TB-500 work (actin / Thymosin Beta-4)?

TB-500's LKKTETQ motif binds monomeric G-actin 1:1 and sequesters it, regulating the cytoskeletal dynamics that drive cell migration and re-epithelialization. X-ray crystallography of a gelsolin-domain-Thymosin Beta-4 hybrid bound to actin established this 1:1 dual-end-capping mechanism ^[3]. Most efficacy data attributed to 'TB-500' were generated with full-length Thymosin Beta-4, not the 7-mer ^[4].

How does BPC-157 work compared to TB-500?

BPC-157 works through a cytoprotective and angiogenic route — up-regulating VEGFR2 with downstream Akt-eNOS signaling and modulating the nitric-oxide system ^[2] — while TB-500 works through actin sequestration that regulates cell migration ^[3]. They are described as complementary but largely non-overlapping mechanisms, which is the rationale for pairing them in the blend.

Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?

Both promote angiogenesis by distinct routes in preclinical models. BPC-157 up-regulates VEGFR2 and promotes its internalization with downstream VEGFR2-Akt-eNOS signaling, increasing vessel density and blood-flow recovery in ischemic muscle ^[2]. Thymosin Beta-4, TB-500's parent, promotes endothelial migration and angiogenesis, including in aged animals with otherwise poor wound healing ^[4].

Evidence and efficacy

What is the BPC-157 and TB-500 blend used for in research?

Its two components occupy complementary nodes of a tissue-repair network in preclinical work: BPC-157 for cytoprotection, angiogenesis, and tendon/ligament repair in rodent models ^[1][2], and TB-500 / Thymosin Beta-4 for cell migration, re-epithelialization, and wound healing in animal and biochemical models ^[4]. The assembled blend itself has not been tested in a controlled study.

Does the BPC-157 TB-500 blend help tendon and ligament injuries?

The tendon/ligament evidence is preclinical and single-compound. BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, and microscopic measures ^[1], and Thymosin Beta-4 is associated with connective-tissue repair in animal models ^[4]. No controlled study has tested the combined blend in tendon or ligament injury.

Does BPC-157 and TB-500 help muscle tears and recovery?

Muscle-repair signals are preclinical and single-compound: BPC-157 has been studied in rat muscle-injury models ^[2], and Thymosin Beta-4 is reported to recruit repair cells to injured muscle ^[4]. A notable counter-result: in mdx mice, chronic Thymosin Beta-4 increased regenerating fibers but did not improve strength or cardiac function ^[4]. No combination muscle-recovery trial exists.

Does the BPC-157 TB-500 blend help wound healing?

Wound-healing evidence is preclinical and single-compound: Thymosin Beta-4 accelerated re-epithelialization, contraction, collagen deposition, and angiogenesis in animal wound models ^[4], and BPC-157 shows cytoprotective and angiogenic activity across tissues ^[2]. No controlled study has tested the assembled blend in wound healing.

Is there any study showing BPC-157 and TB-500 work better together (synergy)?

No. No peer-reviewed study has defined a synergy ratio, dose, or endpoint for the two peptides given together. A 2025 systematic review of BPC-157 (36 studies, only 1 human, 'no clinical safety data') makes no mention of TB-500 or any combination ^[6]. Synergy is extrapolated from each peptide's separately characterized mechanism, not demonstrated in a controlled combination study.

Are there human clinical trials on the BPC-157 + TB-500 combination?

There are no controlled clinical trials of the combination for any indication. Human data exist only for the individual constituents and are thin: BPC-157 has three small pilot studies, and 'TB-500' human data are for full-length Thymosin Beta-4 (Phase 1 IV studies) ^[10], not the heptapeptide ^[5]. The blend's human efficacy and combination safety are unproven.

What is the latest research on BPC-157 and TB-500?

The freshest defensible literature is review-level: a 2025 systematic review ^[6] and a 2025 narrative review ^[7] of BPC-157, both concluding the evidence is low-tier and BPC-157 should be treated as investigational, and a 2026 Sports Medicine narrative review listing both BPC-157 and TB-500, noting animal-model promise but scarce human safety data and no regulatory approval ^[8].

Safety

What are the side effects of BPC-157 and TB-500?

The assembled blend has no controlled human safety data. Component human data are limited: a Phase 1 study of full-length Thymosin Beta-4 was well tolerated ^[10], but a 2026 review cautions that rigorous human safety data for unapproved musculoskeletal peptides are scarce, with potential for serious harm ^[8]. The principal theoretical concern is the pro-angiogenic, pro-migratory tumor signal associated with Thymosin Beta-4.

Does TB-500 cause cancer or promote tumor growth?

Thymosin Beta-4 has been implicated in tumor metastasis and angiogenesis — the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression, a concern that compounds when two pro-repair peptides are combined ^[4]. This is a recognized safety signal, not a demonstrated effect of the blend; no carcinogenicity data exist for the combination.

Dosing, handling, and pharmacokinetics

What is the half-life of BPC-157 and TB-500?

No validated human pharmacokinetic half-life exists for either constituent at research-use doses, and none for the blend. BPC-157's elimination half-life was reported as under 30 minutes in a rat/dog PK study. Human IV full-length Thymosin Beta-4 showed dose-proportional PK ^[10], but no specific half-life is established for the TB-500 heptapeptide.

How do you reconstitute a BPC-157 / TB-500 blend (10mg)?

Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated ^[11]. Commercial vials are commonly labeled with a combined per-vial mass (e.g. 10 mg + 10 mg), but product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed. No human-use reconstitution instructions apply to a research chemical.

How often should you inject BPC-157 and TB-500?

There is no validated human injection frequency for the blend. The underlying animal studies use widely differing schedules (e.g. Thymosin Beta-4 at 150 microg twice weekly for 6 months in one mouse study) ^[4], and community frequency protocols have no controlled-trial basis. The research framing describes doses studied at X in a species, not human schedules.

How do you cycle BPC-157 and TB-500?

No validated human cycling protocol exists. Community 'loading then maintenance' blend protocols have no controlled-trial basis, and a rat embolic-stroke study found Thymosin Beta-4 dosing non-monotonic (18 mg/kg gave no benefit), undermining 'more is better' loading rationales ^[9]. Component animal studies use widely differing schedules by species and route.

Regulatory and access

Are BPC-157 and TB-500 FDA approved or banned by WADA?

Neither is approved by the FDA for human use, and the blend has no approved therapeutic indication. FDA placed both BPC-157 and 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500' in 503A Category 2 effective the September 29, 2023 list update ^[12][13]. Both constituents are prohibited by WADA (BPC-157 under S0; TB-500 / Thymosin Beta-4 under prohibited peptide/growth-factor categories).

Is Wolverine legal?

Wolverine is not a single regulated product, so its legality is the legality of its two components. Neither BPC-157 nor TB-500 is an FDA-approved drug, and the blend has no approved indication anywhere ^[12][13]. Both are currently 503A Category 2, so compounding access is restricted, and both are WADA-prohibited. This is general information, not legal advice.

Can you get BPC-157 from a compounding pharmacy?

Currently, access is restricted. FDA placed BPC-157 in 503A Category 2 effective the September 29, 2023 update, so it is not within FDA's enforcement-discretion policy for 503A compounding ^[12]. BPC-157 is on the scheduled July 23-24, 2026 PCAC agenda as a candidate under review ^[14] — a scheduled discussion, not a change in current status.

What is the FDA 503A status of Wolverine?

Both of Wolverine's components are 503A Category 2 bulk drug substances, effective FDA's September 29, 2023 list update: BPC-157 and 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500' ^[12][13]. Category 2 means FDA identified significant safety risks and does not afford enforcement discretion ^[11]. Both are on the scheduled July 23-24, 2026 PCAC agenda as candidates for the 503A bulks list ^[14].